AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

AstraZeneca CEO Pascal Soriot said the U.K.-listed company had many reasons to be in the U.S., adding that it was “rapidly transferring manufacturing” across the Atlantic.

Leave a Reply

Your email address will not be published. Required fields are marked *